Opposing Roles of Gut Microbial Metabolites in Regulating CAR-T Cell Efficacy

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Cell  https://doi.org/10.1016/j.cell.2026.09.004
Dr. Markus Perl et al.

Points

Multi center research across three German university hospitals evaluated gut microbiome metabolites in an observational cohort of one hundred twenty nine patients receiving CAR T cell therapy.
Metagenomic profiling identified that low baseline levels of short chain fatty acids like valerate correlated with increased risk of cancer progression following treatment.
Mechanistic testing demonstrated that valerate supplementation improved human CAR T cell function whereas elevated levels of indole metabolites and isovaleric acid impaired overall therapeutic efficacy.
Investigational findings led researchers to design the CARBiome clinical trial assessing microbiota transfer in multiple myeloma patients who previously received antibiotic treatments.
Authors concluded that focusing on biologically active metabolites provides a functional framework for developing diagnostic risk scores and dietary strategies to improve immunotherapy outcomes.

Summary

This study evaluated the impact of gut microbial metabolites on chimeric antigen receptor (CAR)-T cell therapy efficacy in hematological malignancies. Published in Cell by researchers at the Leibniz Institute for Immunotherapy and University Hospital Regensburg alongside German university hospitals in Munich and Heidelberg, the study addressed why nearly 50% of CAR-T patients experience disease relapse or progression. The research sought to identify functional bacterial metabolites using shotgun metagenomics and mass spectrometry to determine whether specific metabolic pathways modulate immune effector function or tumor dynamics.

An observational cohort of 129 patients across three German centers was analyzed to correlate baseline metabolomic profiles with clinical outcomes. Reduced baseline levels of short-chain fatty acids, specifically valeric acid (valerate), strongly correlated with an increased risk of disease progression. Conversely, elevated concentrations of indole metabolites—including indole-3-carboxaldehyde and indole-3-acetic acid—as well as the branched-chain fatty acid isovaleric acid, were associated with adverse therapeutic outcomes. In vitro and in vivo models confirmed that valeric acid supplementation enhanced human and murine CAR-T cell functionality, whereas indole-3-carboxaldehyde and isovaleric acid impaired CAR-T cell efficacy and promoted tumor growth.

The authors conclude that microbial metabolites, rather than bacterial composition alone, serve as key biological drivers determining CAR-T therapy success. These findings led to the development of a metabolite-based risk score for clinical stratification and provided the mechanistic basis for the CARBiome clinical trial evaluating microbiota transfer in multiple myeloma patients. The study demonstrates that targeted dietary interventions, metabolite supplementation, or microbiota transfer represent promising metabolite-guided strategies to optimize clinical outcomes in cancer immunotherapy.

Link to the article: https://www.cell.com/cell/fulltext/S0092-8674(26)01073-1?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867426010731%3Fshowall%3Dtrue

References

Perl, M., Guetter, S., Shah, D., Holzinger, S., Becker, L., Tariq, M., Menauer, P., Delahais, S., Lutzny-Geier, G., Scherer, J. N., Göttert, S., Herfeld, K., Heinrich, P., Kreitmeier, K. G., Gebhard, C., Herr, W., Trefny, M. P., Doerr, J., Sameri, S., … Poeck, H. (2026). Opposing functions of gut immunomodulatory metabolites on CAR-T therapy. Cell, S0092867426010731. https://doi.org/10.1016/j.cell.2026.09.004